US5019761049
US5019761049
Kyverna Therapeutics, Inc.
Loading chart...
Financials
Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Details
| Breakdown | 2025 | 2024 | Change % |
|---|---|---|---|
| Total Revenue | -- | -- | -- |
| Cost of Revenue | -- | -- | -- |
| Gross Profit | -- | -- | -- |
| 169.827.000 | 142.604.000 | 19.1% | |
| Operating Income | -169.827.000 | -142.604.000 | 19.1% |
| Pretax Income | -161.307.000 | -127.477.000 | 26.5% |
| Net Income Common Stockholders | -161.307.000 | -127.477.000 | 26.5% |
| -- | -- | -- | |
| -- | -- | -- |